These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15472793)

  • 21. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children.
    Bitnun A; Sochett E; Babyn P; Holowka S; Stephens D; Read S; King SM
    AIDS; 2003 Jun; 17(9):1319-27. PubMed ID: 12799553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome.
    Kosmiski LA; Kuritzkes DR; Lichtenstein KA; Glueck DH; Gourley PJ; Stamm ER; Scherzinger AL; Eckel RH
    AIDS; 2001 Oct; 15(15):1993-2000. PubMed ID: 11600828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.
    Mallal SA; John M; Moore CB; James IR; McKinnon EJ
    AIDS; 2000 Jul; 14(10):1309-16. PubMed ID: 10930144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
    Valantin MA; Lanoy E; Bentata M; Kalmykova O; Boutekadjirt A; Allavena C; Rozenbaum W; Peytavin G; Amellal B; Calvez V; Costagliola D; Katlama C;
    HIV Med; 2008 Oct; 9(8):625-35. PubMed ID: 18624724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.
    Miller J; Carr A; Emery S; Law M; Mallal S; Baker D; Smith D; Kaldor J; Cooper DA
    HIV Med; 2003 Jul; 4(3):293-301. PubMed ID: 12859330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
    Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A
    AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
    Moyle GJ; Sabin CA; Cartledge J; Johnson M; Wilkins E; Churchill D; Hay P; Fakoya A; Murphy M; Scullard G; Leen C; Reilly G;
    AIDS; 2006 Oct; 20(16):2043-50. PubMed ID: 17053350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
    Benn P; Sauret-Jackson V; Cartledge J; Ruff C; Sabin CA; Moyle G; Linney A; Reilly G; Edwards SG
    HIV Med; 2009 Jul; 10(6):351-5. PubMed ID: 19490181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.
    Hammond E; McKinnon E; Nolan D
    Clin Infect Dis; 2010 Sep; 51(5):591-9. PubMed ID: 20645860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.
    Guaraldi G; Zona S; Cossarizza A; Vernacotola L; Carli F; Lattanzi A; Nardini G; Orlando G; Garlassi E; Termini R; Garau M
    Int J STD AIDS; 2014 Mar; 25(3):207-12. PubMed ID: 24216034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Hassink EA; van Eck-Smit BL; Borleffs JC; Lange JM; Reiss P
    HIV Clin Trials; 2007; 8(5):337-44. PubMed ID: 17956835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psoas muscle attenuation measurement with computed tomography indicates intramuscular fat accumulation in patients with the HIV-lipodystrophy syndrome.
    Torriani M; Hadigan C; Jensen ME; Grinspoon S
    J Appl Physiol (1985); 2003 Sep; 95(3):1005-10. PubMed ID: 12766180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy.
    Cooper DA; Cordery DV; Reiss P; Henry K; Nelson M; O'Hearn M; Reynes J; Arastéh K; Chung J; Rowell L; Guimaraes D; Bertasso A;
    HIV Med; 2011 Jan; 12(1):31-9. PubMed ID: 20497250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy.
    van der Valk M; Casula M; Weverlingz GJ; van Kuijk K; van Eck-Smit B; Hulsebosch HJ; Nieuwkerk P; van Eeden A; Brinkman K; Lange J; de Ronde A; Reiss P
    Antivir Ther; 2004 Jun; 9(3):385-93. PubMed ID: 15259901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy.
    Walmsley S; Cheung AM; Fantus G; Gough K; Smaill F; Azad ; Diong C; Raboud J
    HIV Clin Trials; 2008; 9(5):314-23. PubMed ID: 18977720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.
    Carr A; Miller J; Law M; Cooper DA
    AIDS; 2000 Feb; 14(3):F25-32. PubMed ID: 10716495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.
    Dubé MP; Parker RA; Tebas P; Grinspoon SK; Zackin RA; Robbins GK; Roubenoff R; Shafer RW; Wininger DA; Meyer WA; Snyder SW; Mulligan K
    AIDS; 2005 Nov; 19(16):1807-18. PubMed ID: 16227788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.
    Saint-Marc T; Partisani M; Poizot-Martin I; Rouviere O; Bruno F; Avellaneda R; Lang JM; Gastaut JA; Touraine JL
    AIDS; 2000 Jan; 14(1):37-49. PubMed ID: 10714566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
    Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.